Genetically engineered stem cells expressing cytosine deaminase and interferon-β migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects

  • Authors: Bo-Rim Yi, Si-Na O, Nam-Hee Kang, Kyung-A Hwang, Seung U. Kim, Eui-Bae Jeung, Yun-Bae Kim, Gang-Joon Heo, Kyung-Chul Choi
  • View Affiliations

  • Published online on: Friday, July 15, 2011
  • Pages: 833-839
  • DOI: 10.3892/ijo.2011.1126

Abstract

Recent studies have shown that genetically engineered stem cells (GESTECs) produce suicide enzymes that convert non-toxic pro-drugs to toxic metabolites which selectively migrate toward tumor sites and reduce tumor growth. In the present study, we evaluated whether these GESTECs are capable of migrating to lung cancer cells and examined the potential therapeutic efficacy of gene-directed enzyme pro-drug therapy against lung cancer cells in vitro. A modified transwell migration assay was performed to determine the migratory capacity of GESTECs to lung cancer cells. GESTECs [i.e., HB1.F3.CD or HB1.F3.CD.interferon-β (IFN-β)] engineered to express a suicide gene, cytosine deaminase (CD), selectively migrated toward lung cancer cells. Treatment of a human non-small cell lung carcinoma cell line (A549, a lung carcinoma derived from human lung epithelial cells) with the pro-drug 5-fluorocytosine (5-FC) in the presence of HB1.F3.CD or HB1.F3.CD.IFN-β cells resulted in the inhibition of lung cancer cell growth. Based on the data presented herein, we suggest that GESTECs expressing CD may have a potent advantage for selective treatment of lung cancers. Furthermore, GESTECs expressing fusion genes (i.e., CD and IFN-β) may have a synergic antitumor effect on lung cancer cells.
Journal Cover

October 2011
Volume 39 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

2012 Impact Factor: 2.657
Ranked #31/196 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yi, B., O, S., Kang, N., Hwang, K., Kim, S., Jeung, E., Kim, Y., Heo, G., & Choi, K. (2011). Genetically engineered stem cells expressing cytosine deaminase and interferon-β migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects. International Journal of Oncology, 39(4), 833-839.
MLA
Yi, O, Kang, Hwang, Kim, Jeung, Kim, Heo, and Kyung-Chul Choi. "Genetically engineered stem cells expressing cytosine deaminase and interferon-β migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects." International Journal of Oncology International Journal of Oncology 39.4 (2011): 833-839.
Chicago
Yi, O, Kang, Hwang, Kim, Jeung, Kim, Heo, and Kyung-Chul Choi. "Genetically engineered stem cells expressing cytosine deaminase and interferon-β migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects." International Journal of Oncology International Journal of Oncology 39 no. 4 (2011): 833-839.